ImmunoGen, Inc. (IMGN) was a big mover last session with its shares surging almost 72% on the day. The upside was owing to the company’s presentation of encouraging Phase 1 trial results of its experimental ovarian cancer treatment, mirvetuximab soravtansine (IMGN853). Shares rallied, hitting a 14-month high of $15.44. This development led to far more shares changing hands yesterday than in a normal session. This continues the recent uptrend of the company as the stock has over 83% in the past one-month time frame.
This biotechnology company that develops targeted anticancer therapeutics has seen no estimate revision in the last 7 days. The Zacks Consensus Estimate hasn’t been in trend either. Yesterday’s sharp climb is encouraging though, so make sure to keep a close watch on this firm in the near future.
ImmunoGen currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Investors interested in the Med-Drugs industry may, however, consider Indivior PLC (INVVY) which sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment